Apolipoportein-A1 gene polymorphisms in patients with positive serology for Chagas. Preliminary results
Over the last few decades, several markers of chagasic cardiomyopathy progression have been proposed; however, none of them reliably predict the progression of the disease and the origin of cardiac abnormalities. Genetic approaches have focused on genes related to the immune response,...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Artículo revista |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2022
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/39033 |
| Aporte de: |
| id |
I10-R327-article-39033 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| format |
Artículo revista |
| topic |
APO-A1 polymorphisms chagasic cardiomyopathy association study polimorfismos de APO-A1 miocardiopatia chagasica estudio de asociación |
| spellingShingle |
APO-A1 polymorphisms chagasic cardiomyopathy association study polimorfismos de APO-A1 miocardiopatia chagasica estudio de asociación Fernández Spector, H Velázquez López, DA Gómez, DS Argüello Hoyos, P Blasco, R Bazán, C Rivarola, W Paglini, P Lo Presti , MS Apolipoportein-A1 gene polymorphisms in patients with positive serology for Chagas. Preliminary results |
| topic_facet |
APO-A1 polymorphisms chagasic cardiomyopathy association study polimorfismos de APO-A1 miocardiopatia chagasica estudio de asociación |
| author |
Fernández Spector, H Velázquez López, DA Gómez, DS Argüello Hoyos, P Blasco, R Bazán, C Rivarola, W Paglini, P Lo Presti , MS |
| author_facet |
Fernández Spector, H Velázquez López, DA Gómez, DS Argüello Hoyos, P Blasco, R Bazán, C Rivarola, W Paglini, P Lo Presti , MS |
| author_sort |
Fernández Spector, H |
| title |
Apolipoportein-A1 gene polymorphisms in patients with positive serology for Chagas. Preliminary results |
| title_short |
Apolipoportein-A1 gene polymorphisms in patients with positive serology for Chagas. Preliminary results |
| title_full |
Apolipoportein-A1 gene polymorphisms in patients with positive serology for Chagas. Preliminary results |
| title_fullStr |
Apolipoportein-A1 gene polymorphisms in patients with positive serology for Chagas. Preliminary results |
| title_full_unstemmed |
Apolipoportein-A1 gene polymorphisms in patients with positive serology for Chagas. Preliminary results |
| title_sort |
apolipoportein-a1 gene polymorphisms in patients with positive serology for chagas. preliminary results |
| description |
Over the last few decades, several markers of chagasic cardiomyopathy progression have been proposed; however, none of them reliably predict the progression of the disease and the origin of cardiac abnormalities. Genetic approaches have focused on genes related to the immune response, but few have studied genes associated with cardiac function. Apolipoprotein-A1 (APO-A1) is the main component of high-density lipoproteins, with known cardioprotective effects; polymorphisms in this gene have been associated with coronary diseases. The purpose of this study was to analyze the role of APO-A1 genetic variants in the development of chronic chagasic cardiomyopathy, in patients from the Province of Córdoba.
Blood samples from 91 patients with positive serology for Chagas, from the city of Córdoba (Hospital Nacional de Clínicas, Clínica Sucre and Hospital San Roque) were analyzed. The patients were classified as: G1 (n=49): without cardiac alterations, G2 (n=32): with mild cardiac alterations (electrocardiographic alterations) and G3 (n=10): with severe cardiac alterations (electrocardiographic and echocardiographic alterations). APO-A1 G-75A (rs670) and C+83T (rs5069) polymorphisms were determined by PCR-RFLP. Differences between allelic and genotypic frequencies were analyzed using chi-square/Fisher's exact test and logistic regression.
Both allele and genotypic frequencies for both polymorphisms were similar between the 3 groups studied and were not associated with the development (G1 vs G2+G3) or the progression (G2 vs G3) of cardiomyopathy. Logistic regression analysis showed that exposure to the less frequent allele of each polymorphism was not related to development [OR rs670_A=1.21 (0.67-2.17); OR rs5069_T=0.91 (0.51-1.65)] or with progression [OR rs670_A=1.04 (0.39-2.80); OR rs5069_T=2.14 (0.79-5.77)] of chagasic cardiomyopathy. However, being heterozygous for the rs5069 polymorphism insinuates as a possible predictor for the development of cardiomyopathy (p=0.0787) in relation to being homozygous for the most frequent allele.
The results obtained to date suggest that APO-A1 genetic variants would not have a significant contribution to the development of chronic chagasic cardiomyopathy in the population studied; the inclusion of a larger number of patients is necessary for more conclusive results.
|
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2022 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/39033 |
| work_keys_str_mv |
AT fernandezspectorh apolipoporteina1genepolymorphismsinpatientswithpositiveserologyforchagaspreliminaryresults AT velazquezlopezda apolipoporteina1genepolymorphismsinpatientswithpositiveserologyforchagaspreliminaryresults AT gomezds apolipoporteina1genepolymorphismsinpatientswithpositiveserologyforchagaspreliminaryresults AT arguellohoyosp apolipoporteina1genepolymorphismsinpatientswithpositiveserologyforchagaspreliminaryresults AT blascor apolipoporteina1genepolymorphismsinpatientswithpositiveserologyforchagaspreliminaryresults AT bazanc apolipoporteina1genepolymorphismsinpatientswithpositiveserologyforchagaspreliminaryresults AT rivarolaw apolipoporteina1genepolymorphismsinpatientswithpositiveserologyforchagaspreliminaryresults AT paglinip apolipoporteina1genepolymorphismsinpatientswithpositiveserologyforchagaspreliminaryresults AT loprestims apolipoporteina1genepolymorphismsinpatientswithpositiveserologyforchagaspreliminaryresults AT fernandezspectorh polimorfismosdelgendelaapolipoporteinaa1enpacientesconserologiapositivaparachagasresultadospreliminares AT velazquezlopezda polimorfismosdelgendelaapolipoporteinaa1enpacientesconserologiapositivaparachagasresultadospreliminares AT gomezds polimorfismosdelgendelaapolipoporteinaa1enpacientesconserologiapositivaparachagasresultadospreliminares AT arguellohoyosp polimorfismosdelgendelaapolipoporteinaa1enpacientesconserologiapositivaparachagasresultadospreliminares AT blascor polimorfismosdelgendelaapolipoporteinaa1enpacientesconserologiapositivaparachagasresultadospreliminares AT bazanc polimorfismosdelgendelaapolipoporteinaa1enpacientesconserologiapositivaparachagasresultadospreliminares AT rivarolaw polimorfismosdelgendelaapolipoporteinaa1enpacientesconserologiapositivaparachagasresultadospreliminares AT paglinip polimorfismosdelgendelaapolipoporteinaa1enpacientesconserologiapositivaparachagasresultadospreliminares AT loprestims polimorfismosdelgendelaapolipoporteinaa1enpacientesconserologiapositivaparachagasresultadospreliminares |
| first_indexed |
2024-09-03T21:04:00Z |
| last_indexed |
2024-09-03T21:04:00Z |
| _version_ |
1809210346863329280 |
| spelling |
I10-R327-article-390332024-04-15T16:14:45Z Apolipoportein-A1 gene polymorphisms in patients with positive serology for Chagas. Preliminary results Polimorfismos del gen de la apolipoporteína-A1 en pacientes con serología positiva para Chagas. Resultados preliminares Fernández Spector, H Velázquez López, DA Gómez, DS Argüello Hoyos, P Blasco, R Bazán, C Rivarola, W Paglini, P Lo Presti , MS APO-A1 polymorphisms chagasic cardiomyopathy association study polimorfismos de APO-A1 miocardiopatia chagasica estudio de asociación Over the last few decades, several markers of chagasic cardiomyopathy progression have been proposed; however, none of them reliably predict the progression of the disease and the origin of cardiac abnormalities. Genetic approaches have focused on genes related to the immune response, but few have studied genes associated with cardiac function. Apolipoprotein-A1 (APO-A1) is the main component of high-density lipoproteins, with known cardioprotective effects; polymorphisms in this gene have been associated with coronary diseases. The purpose of this study was to analyze the role of APO-A1 genetic variants in the development of chronic chagasic cardiomyopathy, in patients from the Province of Córdoba. Blood samples from 91 patients with positive serology for Chagas, from the city of Córdoba (Hospital Nacional de Clínicas, Clínica Sucre and Hospital San Roque) were analyzed. The patients were classified as: G1 (n=49): without cardiac alterations, G2 (n=32): with mild cardiac alterations (electrocardiographic alterations) and G3 (n=10): with severe cardiac alterations (electrocardiographic and echocardiographic alterations). APO-A1 G-75A (rs670) and C+83T (rs5069) polymorphisms were determined by PCR-RFLP. Differences between allelic and genotypic frequencies were analyzed using chi-square/Fisher's exact test and logistic regression. Both allele and genotypic frequencies for both polymorphisms were similar between the 3 groups studied and were not associated with the development (G1 vs G2+G3) or the progression (G2 vs G3) of cardiomyopathy. Logistic regression analysis showed that exposure to the less frequent allele of each polymorphism was not related to development [OR rs670_A=1.21 (0.67-2.17); OR rs5069_T=0.91 (0.51-1.65)] or with progression [OR rs670_A=1.04 (0.39-2.80); OR rs5069_T=2.14 (0.79-5.77)] of chagasic cardiomyopathy. However, being heterozygous for the rs5069 polymorphism insinuates as a possible predictor for the development of cardiomyopathy (p=0.0787) in relation to being homozygous for the most frequent allele. The results obtained to date suggest that APO-A1 genetic variants would not have a significant contribution to the development of chronic chagasic cardiomyopathy in the population studied; the inclusion of a larger number of patients is necessary for more conclusive results. A lo largo de las últimas décadas se han propuesto diversos marcadores de progresión de la miocardiopatía chagásica; sin embargo, ninguno de ellos predice fehacientemente la progresión de la enfermedad y el origen de las alteraciones cardiacas. Los enfoques genéticos se han centrado en genes relacionados a la respuesta inmune, pero pocos han estudiado genes asociados a la función cardiaca. La Apolipoproteína-A1 (APO-A1) es el componente principal de las lipoproteínas de alta densidad, con conocidos efectos cardioprotectores; polimorfismos en este gen han sido asociados a enfermedades coronarias. El objetivo del presente trabajo fue analizar el papel de variantes genéticas de APO-A1 en el desarrollo de la miocardiopatía chagásica crónica, en pacientes de la Provincia de Córdoba. Se analizaron muestras de sangre de 91 pacientes con serología positiva para Chagas, de la ciudad de Córdoba (Hospital Nacional de Clínicas, Clínica Sucre y Hospital San Roque). Los pacientes se clasificaron en: G1(n=49): sin cardiopatía, G2(n=32): con cardiopatía leve (alteraciones electrocardiográficas) y G3(n=10): con cardiopatía severa (alteraciones electrocardiográficas y ecocardiográficas). Los polimorfismos G–75A (rs670) y C+83T (rs5069) se determinaron por PCR-RFLP. Las diferencias entre las frecuencias alélicas y genotípicas se analizaron mediante chi cuadrado/test exacto de Fisher y regresión logística. Tanto las frecuencias alélicas como las frecuencias genotípicas encontradas para ambos polimorfismos fueron similares entre los 3 grupos estudiados y no se asociaron al desarrollo (G1 vs G2+G3) o la progresión (G2 vs G3) de la miocardiopatía. El análisis de regresión logística demostró que la exposición al alelo menos frecuente de cada polimorfismo no se relacionó con el desarrollo [OR rs670_A=1,21(0,67-2,17); OR rs5069_T=0,91 (0,51-1,65)] ni con la progresión [OR rs670_A=1,04(0,39-2,80); OR rs5069_T=2,14 (0,79-5,77)] de la miocardiopatía chagásica. Sin embargo, el ser heterocigota para el polimorfismo rs5069 se insinúa como un posible predictor para el desarrollo de la miocardiopatía (p=0,0787) con relación al homocigota para el alelo más frecuente. Los resultados obtenidos hasta el momento sugieren que las variantes genéticas de APO-A1 no tendrían un aporte significativo en el desarrollo de la miocardiopatía chagásica crónica en la población estudiada; la inclusión de una mayor cantidad de pacientes es necesaria para resultados más concluyentes. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2022-10-26 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion texto https://revistas.unc.edu.ar/index.php/med/article/view/39033 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 79 No. Suplemento JIC XXIII (2022): Suplemento JIC XXIII Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 79 Núm. Suplemento JIC XXIII (2022): Suplemento JIC XXIII Revista da Faculdade de Ciências Médicas de Córdoba; v. 79 n. Suplemento JIC XXIII (2022): Suplemento JIC XXIII 1853-0605 0014-6722 Derechos de autor 2022 Universidad Nacional de Córdoba http://creativecommons.org/licenses/by-nc/4.0 |